The collaboration is intended to yield new small molecule drugs that stimulate tumor-specific immune responses, by combining Kumquat’s platform and focus on first-in-class therapeutics with the cancer development focus and commercialization expertise of Lilly—whose Lilly Asia Ventures venture fund is among five investors that have invested a total more than $100 million in Kumquat. Exactly which small molecule inhibitors Kumquat and Lilly plan to deploy against cancer were not disclosed.